Edward N. Libby - Concepedia

Author

Edward N. Libby

Also Known As

E Libby, E. Libby, E. Libby, E. N. Libby, E.N. Libby, E.N. Libby, Edward Libby, Edward N Libby, Edward N. Libby, Tamang, David L

159

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

University of Washington Fred Hutch Cancer Center University of Washington Medical Center University College London Memorial Sloan Kettering Cancer Center

About

Edward N. Libby is an author at University of Washington specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	26	1.9K
2	Health Sciences	9	9	387
3	Public Health	5	5	166
4	Blood Transplantation	2	2	54
5	Cardiothoracic Surgery	1	1	12

Edward N. Libby

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study Sagar Lonial, Hans C. Lee, Ashraf Badros, The Lancet Oncology Hematological MalignancyMedicinePathologyBelantamab MafodotinCancer Treatment	2019	772
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, New England Journal of Medicine	2021	609
Global Burden of Multiple Myeloma Andrew J. Cowan, Christine A. Allen, Aleksandra Barać, JAMA Oncology	2018	600
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Constantine S. Tam, Stephen Opat, Shirley D’Sa, Blood	2020	432
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma Paul G. Richardson, Susanna Jacobus, Edie Weller, New England Journal of Medicine	2022	428
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma Franck Morschhauser, Nathan Fowler, Pierre Feugier, New England Journal of Medicine	2018	357
Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, The Lancet Oncology Hematological MalignancyMedicineImmunologyExpansion Phase 1Immune Checkpoint Inhibitor	2018	235
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Blood Cancer Journal	2019	210
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial Andrew J. Yee, William Bensinger, Jeffrey G. Supko, The Lancet Oncology Hematological MalignancyHealth SciencesMedicineImmunologyHematology	2016	193
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma Ang Li, Qian Wu, Suhong Luo, Journal of the National Comprehensive Cancer Network	2019	144

Page 1